Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients.

Resmini E, Parodi A, Savarino V, Greco A, Rebora A, Minuto F, Ferone D.

J Clin Endocrinol Metab. 2007 Jun;92(6):2119-24. Epub 2007 Apr 3.

PMID:
17405840
2.

Prolonged orocecal transit time enhances serum bile acids through bacterial overgrowth, contributing factor to gallstone disease.

Kaur J, Rana SV, Gupta R, Gupta V, Sharma SK, Dhawan DK.

J Clin Gastroenterol. 2014 Apr;48(4):365-9. doi: 10.1097/MCG.0b013e3182a14fba.

PMID:
24598592
3.

Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication.

Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, Savarino E, Indiveri F, Savarino V, Ghio M.

Am J Gastroenterol. 2008 May;103(5):1257-62. doi: 10.1111/j.1572-0241.2007.01758.x. Epub 2008 Apr 16.

PMID:
18422815
4.

Clinical value of radionuclide small intestine transit time measurement combined with lactulose hydrogen breath test for the diagnosis of bacterial overgrowth in irritable bowel syndrome.

Ning Y, Lou C, Huang Z, Chen D, Huang H, Chen L, Zhang B, Dai N, Zhao J, Zhen X.

Hell J Nucl Med. 2016 May-Aug;19(2):124-9. doi: 10.1967/s002449910365. Epub 2016 Jun 22.

5.

Orocecal transit time and small intestinal bacterial overgrowth in type 2 diabetes patients from North India.

Rana S, Bhansali A, Bhadada S, Sharma S, Kaur J, Singh K.

Diabetes Technol Ther. 2011 Nov;13(11):1115-20. doi: 10.1089/dia.2011.0078. Epub 2011 Jul 19.

PMID:
21770765
6.

Small Intestinal Transit Time Is Delayed in Small Intestinal Bacterial Overgrowth.

Roland BC, Ciarleglio MM, Clarke JO, Semler JR, Tomakin E, Mullin GE, Pasricha PJ.

J Clin Gastroenterol. 2015 Aug;49(7):571-6. doi: 10.1097/MCG.0000000000000257.

PMID:
25319735
7.

[Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].

Liu ZJ, Wei H, Duan LP, Zhu SW, Zhang L, Wang K.

Zhonghua Yi Xue Za Zhi. 2016 Jun 28;96(24):1896-902. doi: 10.3760/cma.j.issn.0376-2491.2016.24.005. Chinese.

PMID:
27373356
8.

Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.

Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y.

J Hepatol. 2010 Nov;53(5):849-55. doi: 10.1016/j.jhep.2010.05.017. Epub 2010 Jul 17.

PMID:
20675008
9.

Transient lactose malabsorption in patients affected by symptomatic uncomplicated diverticular disease of the colon.

Tursi A, Brandimarte G, Giorgetti GM, Elisei W.

Dig Dis Sci. 2006 Mar;51(3):461-5.

PMID:
16614952
10.

Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease.

Rana SV, Sharma S, Malik A, Kaur J, Prasad KK, Sinha SK, Singh K.

Dig Dis Sci. 2013 Sep;58(9):2594-8. doi: 10.1007/s10620-013-2694-x. Epub 2013 May 7.

PMID:
23649377
11.

Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon.

Tursi A, Brandimarte G, Giorgetti GM, Elisei W.

World J Gastroenterol. 2005 May 14;11(18):2773-6.

12.

Delayed small intestinal transit in patients with long-standing type 1 diabetes mellitus: investigation of the relationships with clinical features, gastric emptying, psychological distress, and nutritional parameters.

Faria M, Pavin EJ, Parisi MC, Lorena SL, Brunetto SQ, Ramos CD, Pavan CR, Mesquita MA.

Diabetes Technol Ther. 2013 Jan;15(1):32-8. doi: 10.1089/dia.2012.0158. Epub 2012 Nov 5.

PMID:
23126582
13.
14.

Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication.

Parodi A, Paolino S, Greco A, Drago F, Mansi C, Rebora A, Parodi A, Savarino V.

Clin Gastroenterol Hepatol. 2008 Jul;6(7):759-64. doi: 10.1016/j.cgh.2008.02.054. Epub 2008 May 5.

PMID:
18456568
15.

Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy.

Lunia MK, Sharma BC, Sachdeva S.

Hepatol Int. 2013 Mar;7(1):268-73. doi: 10.1007/s12072-012-9360-9. Epub 2012 Mar 15.

PMID:
26201641
16.

The prevalence of small intestinal bacterial overgrowth and methane production in patients with myelomeningocele and constipation.

Ojetti V, Bruno G, Paolucci V, Triarico S, D'aversa F, Ausili E, Gasbarrini A, Rendeli C.

Spinal Cord. 2014 Jan;52(1):61-4. doi: 10.1038/sc.2013.131. Epub 2013 Nov 19.

PMID:
24247567
17.

Gastrointestinal motility disorder assessment in systemic sclerosis.

Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A, Berdini M, Di Sario A, Bendia E, Bonazzi P, Scarpellini E, Laterza L, Savarino V, Gasbarrini A.

Rheumatology (Oxford). 2013 Jun;52(6):1095-100. doi: 10.1093/rheumatology/kes429. Epub 2013 Feb 4.

PMID:
23382360
18.

A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.

Zhao J, Zheng X, Chu H, Zhao J, Cong Y, Fried M, Fox M, Dai N.

Neurogastroenterol Motil. 2014 Jun;26(6):794-802. doi: 10.1111/nmo.12331. Epub 2014 Mar 18.

PMID:
24641100
19.

Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.

Furnari M, Parodi A, Gemignani L, Giannini EG, Marenco S, Savarino E, Assandri L, Fazio V, Bonfanti D, Inferrera S, Savarino V.

Aliment Pharmacol Ther. 2010 Oct;32(8):1000-6. doi: 10.1111/j.1365-2036.2010.04436.x. Epub 2010 Aug 18.

20.

Relationship of cytokines, oxidative stress and GI motility with bacterial overgrowth in ulcerative colitis patients.

Rana SV, Sharma S, Kaur J, Prasad KK, Sinha SK, Kochhar R, Malik A, Morya RK.

J Crohns Colitis. 2014 Aug;8(8):859-65. doi: 10.1016/j.crohns.2014.01.007. Epub 2014 Jan 21.

PMID:
24456736

Supplemental Content

Support Center